Compare CGEN & KRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEN | KRMD |
|---|---|---|
| Founded | 1993 | 1980 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.1M | 177.8M |
| IPO Year | 2001 | 2019 |
| Metric | CGEN | KRMD |
|---|---|---|
| Price | $2.02 | $4.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.00 | ★ $6.50 |
| AVG Volume (30 Days) | ★ 440.2K | 101.3K |
| Earning Date | 05-18-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,127,366.00 |
| Revenue This Year | N/A | $20.32 |
| Revenue Next Year | $75.09 | $17.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $1.30 | $2.91 |
| 52 Week High | $3.24 | $6.61 |
| Indicator | CGEN | KRMD |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 54.17 |
| Support Level | $1.98 | $4.05 |
| Resistance Level | $2.35 | $4.28 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 20.97 | 73.57 |
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.